The tumor suppressor p53 exerts important protective functions towards DNA-damaging agents. Its inactivation by allelic deletions or point mutations within the P53 gene as well as complex formation of wildtype p53 with cellular or viral proteins is a common and crucial event in carcinogenesis. Mutations increase the half-life of the p53 protein allowing the immunohistochemical detection and anti-p53 antibody formation. Distinct G to T point mutations in codon 249 leading to a substitution of the basic amino acid arginine by the neutral amino acid serin are responsible for the altered functionality of the mutant gene product and were originally identified in 8 of 16 Chinese and 5 of 10 African HCC patients. Both groups are frequently exposed to mycotoxin contaminations of their food. Today an average P53 gene mutation rate of 25% is assumed for high-aflatoxin Bi-exposure regions. This is double the rate observed in low-aflatoxin Brexposure countries. Although many HCC patients displaying P53 mutations also suffer from HBV infection, which itself can lead to rearrangements of P53 coding regions or induce the synthesis of viral proteins possibly interacting with p53, the specific G to T transversion within codon 249 of the P53 gene seems to directly reflect the extent of aflatoxin Bi exposure.
Hepatocellular carcinoma (HCC) represents one of the most common lethal tumors worldwide (1) and accounts for up to 30% of all types of malignant tumors in South East Asia and south and equatorial Africa. Chronic hepatitis B and C virus (HBV and HCV, respectively) infection, cirrhosis and aflatoxin Bi exposure are considered the major aetiologic factors of HCC development (2) . Molecular biological techniques have increasingly elucidated the pathogenic mechanisms which induce or maintain malignant hepatocyte transformation, and have provided evidence that inactivation of the tumor suppressor p53 is a common and crucial event in carcinogenesis.
The P53 gene --normal and deranged functions
The P53 gene, located on the short arm of chromosome 17 (17p13), encodes a nuclear phosphoprotein (Fig. l) . The carboxyterminus harbours an oligomerizing function that allows p53 tetramer formation (4) and a DNA-binding activity. A transcriptional trans-activator function resides in the aminoterminus (5, 6) , which is involved in the control of transcription by regulating the interaction of DNA polymerase-alpha with other components of the DNA replication complex (7) . Whereas wildtype p53 is not required for normal ontogenic development in mice (8), it seems to exert pivotal protective functions as "guardian of the genome" (9): DNA-damaging agents like ultraviolet light, gamma-irradiation or certain chemotherapies (10) stimulate intracellular accumulation of p53. In high concentrations p53 inhibits DNA replication and cell growth thus providing sufficient time for DNA repair or ;allowing cytolysis, if the damage exceeds the restoring capacity of the cellular DNA repair systems (9) .
Inactivation of the tumor-suppressing potential can be achieved by (l) allelic deletions or (2) point mutations within the P53 gene as well as by (3) complex formation of wildtype p53 with cellular or viral proteins (Fig. 2) . Abnormal structure and expression of the P53 gene are observed in various hepatoma cell lines (l 1). HBV DNA integration can take place in the short arm of human chromosome 17 (12) near P53 sequences (13) and structural rearrangements and subsequent aberrant transcription of the P53 gene were found in both hepatocarcinoma cell lines and HCC tissues (14). In clonogenic assays using human fibroblast cell lines it was recently demonstrated that the disruption of one P53 gene, with the concomitant reduction of p53 protein levels, was not sufficient to induce increased endogenous gene amplification considered to represent a preneoplastic condition in this system. However, the loss of both P53 alleles in these cells resulted in an increased rate of amplifications in association with the failure to arrest growth (15) .
Point mutations are present in P53 cDNAs derived from astrocytomas, breast cancers, small cell lung cancers, esophageal cancers, osteosarcomas, rhabdomyosarcomas and colon cancers (7) . Germ line P53 mutations occur in families with the Li-Fraumeni syndrome with autosomal dominantly inherited risk of diverse myesenchymal and epithelial neoplasms at multiple sites (16, 17) . Almost 90% of these mutations are clustered in four regions of exons 5-8 of the P53 gene (18; Fig. 1 ). Point mutations affect distinct base pairs and result in the substitution of single amino acids. G to T transversions detected in codon 249 in human HCC (19, 20) lead to a substitution of the basic amino acid of the adeno-and papilloma viruses, respectively, are further examples for p53 inactivating binding partners (27) , which are derived from DNA tumor viruses. Recently, co-immunoprecipitation experiments identified the MDM2 protein, which was encoded and originally described on a mouse double minute chromosome but overexpressed in human sarcomas, as the first cellular binding counterpart of p53 (28, Fig. 1 ). Preliminary data suggest that no p53 mutations occur if MDM2 gene amplification is present. As with viral oncoproteins, large amounts of MDM2 protein may complex and inactivate wiidtype p53 (28) .
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Aflatoxins and HCC
There seems to be a geographical correlation between P53 codon 249 mutation in HCCs and aflatoxin Bl uptake. The described point mutation was originally found in eight of 16 Chinese and five of 10 African patients (19, 20) with both groups living in regions with traditionally high exposure to mycotoxins. None of these mutations were detectable in 20 patients with HCCs recently studied in Great Britain (29) . Only two of 13 HCC DNAs from Germany displayed a C to T and a T to A transversion, respectively, in codons 257 or 273, but not in codon 249 (30) . In all of the latter countries the environmental aflatoxin uptake is low. More recent studies claim a P53 gene mutation rate of 25%for highaflatoxin Brexposure regions (31) . This is twice the rate observed in Iow-aflatoxin Brexposure countries, but still considerably less than previously assumed. Data from 167 patients with HCCs from various geographic areas differing in daily mycotoxin exposure also support the notion that codon 249 mutations of the P53 gene are directly associated with high aflatoxin uptake (32) . Aflatoxin B t, the main food contaminating mycotoxin in China and Africa, is a fungal metabolite, mostly from inappropriately stored grain and is known as a hepatocarcinogen and epidemiologically defined risk factor for HCC development in different species (32, 33) . The involvement of aflatoxins, bioactivated by P450 isoenzymes (34) , in the observed G to T point mutations seems even more likely, because they specifically induce G by T substitutions by reacting almost exclusively with DNA guanines at the N7 position (35) .
Since many HCC patients investigated for p53 mutations also suffer from HBV infection, the relative impact of these factors in the development of HCC is difficult to establish. Integration of HBV DNA during infection leads to manifold rearrangements of cellular DNA that can also affect P53 coding regions. Furthermore HBV DNA integration induces the synthesis of HBV transactivator proteins (36-39) which may inactivate p53 by complex formation. However, the specific G to T point mutation within codon 249 of the P53 gene in HCC DNAs is not pathognomonic for all HCCs but seems to directly reflect the extent of aflatoxin Bi exposure.
